comparemela.com
Home
Live Updates
Flare Therapeutics Presents New Translational Data in Suppor
Flare Therapeutics Presents New Translational Data in Suppor
Flare Therapeutics Presents New Translational Data in Support of Lead Asset FX-909 for the Treatment of Muscle-Invasive Urothelial Cancer at SITC 2023 Annual Meeting
/PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and...
Related Keywords
United States ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
San Diego ,
California ,
Michaela Bowden ,
Prnewswire Flare Therapeutics Inc ,
Society For Immunotherapy Of Cancer ,
Therapeutics Inc ,
Annual Meeting ,
Chief Development Officer ,
Muscle Invasive Urothelial Cancer ,
Progression Free Survival ,
Advanced Urothelial Carcinoma ,
Flare Therapeutics ,
Health Care Amp Hospitals ,
Biotechnology ,
Medical Pharmaceuticals ,
Pharmaceuticals ,
Clinical Trials Amp Medical Discoveries ,